New findings on Januvia bode well for approval

September 18, 2006

Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (Januvia, Merck), currently under review by the FDA, can cause a 2.1 percentage point drop in A1c levels in patients receiving the drug in conjunction with metformin, according to study results released at the 42nd Annual Meeting of the European Association for the Study of Diabetes this week.

Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (Januvia, Merck), currently under review by the FDA, can cause a 2.1 percentage point drop in A1c levels in patients receiving the drug in conjunction with metformin, according to study results released at the 42nd Annual Meeting of the European Association for the Study of Diabetes this week. Patients received either combination treatment with metformin (1,000 mg) and sitagliptin (50 mg twice daily) or just metformin alone. Results showed that 66% of patients in the combination group were able to achieve the target goal of an A1c level of less than 7%, compared with only 38% in the metformin group. A final FDA decision for marketing of Januvia is expected in October.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.